Trial Profile
Prospective, active controlled 12-week study to evaluate effect of exenatide on obesity and non alcoholic fatty liver disease (NAFLD) with elevated liver enzymes in patients with type 2 diabetes mellitus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Oct 2015
Price :
$35
*
At a glance
- Drugs Exenatide (Primary) ; Insulin aspart; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 23 Oct 2015 New trial record.